FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W2000596607> ?p ?o ?g. }

• W2000596607 endingPage "311" @default.
• W2000596607 startingPage "306" @default.
• W2000596607 abstract "SRC activation is associated with cell migration, proliferation, and metastasis. Saracatinib is an oral tyrosine kinase inhibitor (TKI) selective for SRC. We performed this trial to evaluate the efficacy and safety of saracatinib monotherapy in patients with estrogen receptor (ER)(-) and progesterone receptor (PR)(-) metastatic breast cancer (MBC).Patients who had undergone ≤ 1 previous chemotherapy regimen for measurable ER(-) and PR(-) MBC received saracatinib 175 mg orally daily. The primary endpoint was disease control defined as complete response (CR) + partial response (PR) + stable disease (SD) > 6 months. Secondary endpoints included toxicity and progression-free survival (PFS). Levels of circulating tumor cells (CTCs) in response to therapy were measured over time.Nine patients were treated on study. After a median of 2 cycles (range 1-3), no patient had achieved CR, PR, or SD >6 months. The median time to treatment failure was 82 days (12-109 days).The majority (89%) of patients discontinued saracatinib because of disease progression. One patient acquired potentially treatment-related grade 4 hypoxia with interstitial infiltrates and was removed from the study. Common adverse events included fatigue, elevated liver enzymes, nausea, hyponatremia, dyspnea, cough, and adrenal insufficiency.These efficacy results were not sufficiently promising to justify continued accrual to this study. Based on this series, saracatinib does not appear to have significant single-agent activity for the treatment of patients with ER(-)/PR(-) MBC." @default.
• W2000596607 created "2016-06-24" @default.
• W2000596607 creator A5001265699 @default.
• W2000596607 creator A5009811727 @default.
• W2000596607 creator A5011131759 @default.
• W2000596607 creator A5018869140 @default.
• W2000596607 creator A5019035696 @default.
• W2000596607 creator A5019041034 @default.
• W2000596607 creator A5031423623 @default.
• W2000596607 creator A5039225060 @default.
• W2000596607 creator A5047713528 @default.
• W2000596607 creator A5054376605 @default.
• W2000596607 creator A5055628562 @default.
• W2000596607 creator A5068207600 @default.
• W2000596607 creator A5069656105 @default.
• W2000596607 creator A5085875361 @default.
• W2000596607 date "2011-10-01" @default.
• W2000596607 modified "2023-09-29" @default.
• W2000596607 title "Phase II Trial of Saracatinib (AZD0530), an Oral SRC-inhibitor for the Treatment of Patients with Hormone Receptor-negative Metastatic Breast Cancer" @default.
• W2000596607 cites W1532635242 @default.
• W2000596607 cites W1589166971 @default.
• W2000596607 cites W1970962784 @default.
• W2000596607 cites W1974046103 @default.
• W2000596607 cites W1988698939 @default.
• W2000596607 cites W1989901669 @default.
• W2000596607 cites W1990020715 @default.
• W2000596607 cites W1994309500 @default.
• W2000596607 cites W1998936478 @default.
• W2000596607 cites W2009722391 @default.
• W2000596607 cites W2023720844 @default.
• W2000596607 cites W2039469642 @default.
• W2000596607 cites W2040412126 @default.
• W2000596607 cites W2044858733 @default.
• W2000596607 cites W2045792003 @default.
• W2000596607 cites W2049761405 @default.
• W2000596607 cites W2055936726 @default.
• W2000596607 cites W2059854067 @default.
• W2000596607 cites W2109423875 @default.
• W2000596607 cites W2111976640 @default.
• W2000596607 cites W2116153687 @default.
• W2000596607 cites W2124565099 @default.
• W2000596607 cites W2126579741 @default.
• W2000596607 cites W2127283584 @default.
• W2000596607 cites W2160318185 @default.
• W2000596607 cites W2171620938 @default.
• W2000596607 cites W2249514429 @default.
• W2000596607 doi "https://doi.org/10.1016/j.clbc.2011.03.021" @default.
• W2000596607 hasPubMedCentralId "https://www.ncbi.nlm.nih.gov/pmc/articles/3222913" @default.
• W2000596607 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/21729667" @default.
• W2000596607 hasPublicationYear "2011" @default.
• W2000596607 type Work @default.
• W2000596607 sameAs 2000596607 @default.
• W2000596607 citedByCount "116" @default.
• W2000596607 countsByYear W20005966072012 @default.
• W2000596607 countsByYear W20005966072013 @default.
• W2000596607 countsByYear W20005966072014 @default.
• W2000596607 countsByYear W20005966072015 @default.
• W2000596607 countsByYear W20005966072016 @default.
• W2000596607 countsByYear W20005966072017 @default.
• W2000596607 countsByYear W20005966072018 @default.
• W2000596607 countsByYear W20005966072019 @default.
• W2000596607 countsByYear W20005966072020 @default.
• W2000596607 countsByYear W20005966072021 @default.
• W2000596607 countsByYear W20005966072022 @default.
• W2000596607 countsByYear W20005966072023 @default.
• W2000596607 crossrefType "journal-article" @default.
• W2000596607 hasAuthorship W2000596607A5001265699 @default.
• W2000596607 hasAuthorship W2000596607A5009811727 @default.
• W2000596607 hasAuthorship W2000596607A5011131759 @default.
• W2000596607 hasAuthorship W2000596607A5018869140 @default.
• W2000596607 hasAuthorship W2000596607A5019035696 @default.
• W2000596607 hasAuthorship W2000596607A5019041034 @default.
• W2000596607 hasAuthorship W2000596607A5031423623 @default.
• W2000596607 hasAuthorship W2000596607A5039225060 @default.
• W2000596607 hasAuthorship W2000596607A5047713528 @default.
• W2000596607 hasAuthorship W2000596607A5054376605 @default.
• W2000596607 hasAuthorship W2000596607A5055628562 @default.
• W2000596607 hasAuthorship W2000596607A5068207600 @default.
• W2000596607 hasAuthorship W2000596607A5069656105 @default.
• W2000596607 hasAuthorship W2000596607A5085875361 @default.
• W2000596607 hasBestOaLocation W20005966072 @default.
• W2000596607 hasConcept C121608353 @default.
• W2000596607 hasConcept C126322002 @default.
• W2000596607 hasConcept C143998085 @default.
• W2000596607 hasConcept C168563851 @default.
• W2000596607 hasConcept C197934379 @default.
• W2000596607 hasConcept C203092338 @default.
• W2000596607 hasConcept C2775930923 @default.
• W2000596607 hasConcept C2780482068 @default.
• W2000596607 hasConcept C530470458 @default.
• W2000596607 hasConcept C71924100 @default.
• W2000596607 hasConcept C84606932 @default.
• W2000596607 hasConcept C90924648 @default.
• W2000596607 hasConceptScore W2000596607C121608353 @default.
• W2000596607 hasConceptScore W2000596607C126322002 @default.
• W2000596607 hasConceptScore W2000596607C143998085 @default.
• W2000596607 hasConceptScore W2000596607C168563851 @default.
• W2000596607 hasConceptScore W2000596607C197934379 @default.

• next